Novo Nordisk's Two-Speed Week: Paediatric Progress and a Cardiology Retreat Put the Buyback in the Spotlight

Novo Nordisk's buyback at 281.63 DKK clashes with Ziltivekimab trial halt and semaglutide pediatric success, as shares dip 29% from peak.

The arithmetic of Novo Nordisk's share repurchase programme tells a story of its own. Between 4 February and 4 September, the Danish drugmaker bought back 32,034,179 B-shares at an average price of 281.63 Danish kroner, for a total outlay of roughly 9.02 billion kroner. That level of conviction from management lands at an awkward moment, with the stock trading about 29 percent beneath its January peak and the news flow turning distinctly mixed.

The latest blow came on Tuesday, when Novo Nordisk pulled the plug on two more Phase 3 trials of Ziltivekimab in heart failure. An independent data monitoring committee had concluded there was only a "low probability" that the results would diverge from the earlier failed study, which had already missed its goal of reducing heart attacks and strokes. The decision narrows the drug's remaining runway to a single trial in post-heart-attack patients, with readouts not expected until the first half of 2027.

Investors were handed a counterweight on the very same day. Results from the Phase 3 STEP Young study showed that semaglutide hit its primary endpoint in children aged six to under twelve with obesity, delivering superior BMI reduction after 68 weeks compared with placebo. Among those who completed the full course of treatment, 40.4 percent no longer qualified as obese, against zero percent in the placebo arm. The company said safety and tolerability were consistent with earlier studies, with no new signals relating to growth or pubertal development.

That juxtaposition — a paediatric win and a cardiology retreat landing almost simultaneously — helps explain the market's edginess. The shares closed Tuesday at 38.98 euros, down 2.1 percent on the day, and remain a long way from the 52-week high of 54.86 euros reached in late January. Technical indicators do little to brighten the picture: the relative strength index sits at 42.5, the price is roughly 6.2 percent below its 50-day moving average, and annualised volatility of 40 percent points to continued nervousness.

The backdrop has also been complicated by the rollout of the Wegovy tablet in Germany, which began last Friday and has coincided with a 2.8 percent decline in the share price since. China, meanwhile, has started its regulatory review of the oral version of Wegovy, though Novo Nordisk has not indicated when a decision might land.

What makes the current moment particularly delicate is the competitive dynamic with Eli Lilly. The US Food and Drug Administration has approved Mounjaro to lower cardiovascular risk in high-risk type 2 diabetes patients — a move that Reuters reported would intensify pressure on Novo Nordisk's broader GLP-1 expansion. The agreed US price cuts, under which Ozempic and Wegovy will cost 350 dollars per month through the TrumpRx channel, could theoretically boost volumes enough to offset thinner margins, but that remains a bet on scale rather than a certainty.

The bull case rests on the oral tablet finding favour with patients who prefer not to inject, and on the STEP Young data opening up a younger patient segment whose commercial potential is barely priced in. A green light in China would add a further, potentially enormous market. The bear case is equally straightforward: with Ziltivekimab's heart-failure programme now largely dismantled, Novo Nordisk's dependence on semaglutide products has deepened just as Eli Lilly builds out a cardiovascular differentiation of its own.

For now, the share buyback at levels around 281.63 kroner may yet prove a shrewd entry point if the stock recovers. But the immediate focus shifts to the capital markets day in London on 21 September, where management is expected to set out how the pipeline will be reoriented after the Ziltivekimab setback and what role programmes such as STEP Young will play in the growth strategy. Until then, and until the final Ziltivekimab readout in the first half of 2027, the shares are likely to be judged primarily on how quickly the oral Wegovy tablet converts into tangible sales momentum.